RBC Capital analyst Ashish Sabadra raised the firm’s price target on CME Group (CME) to $282 from $269 and keeps a Sector Perform rating on the shares. Near-term market dynamics supported solid volume growth in Q2, while Market and Data Information continues to benefit from increased subscriber growth and pricing tailwinds, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target lowered to $303 from $304 at Morgan Stanley
- CME Group downgraded to Neutral from Buy at UBS
- CME Group price target raised to $303 from $300 at Oppenheimer
- Positive Outlook for CME Group Driven by Risk Management Demand and Strong Financial Position
- CME Group price target lowered to $298 from $299 at Barclays